Company: RVRC
Filing Date: 2025-02-14
Form Type: S-1
Source: 0001213900-25-013823
Chunk: 168

Company: Revium Rx.
Filing Date: 2025-02-14
Form: S-1
Chunk 168
---
-monetary relief will remain available under Nevada law. In addition, each director will continue to be subject to liability for breach of the director’s duty of loyalty to our Company, for acts or omissions not in good faith or involving intentional misconduct, for knowing violations of law, for any transaction from which the director derived an improper personal benefit, and for payment of dividends or approval of stock repurchases or redemptions that are unlawful under Nevada law. The provision also does not affect a director’s responsibilities under any other laws, such as the federal securities laws or state or federal environmental laws.

We have not entered into any agreements with our directors and executive officers that require us to indemnify these persons against expenses, judgments, fines, settlements and other amounts actually and reasonably incurred (including expenses of a derivative action) in connection with any proceeding, whether actual or threatened, to which any such person may be made a party by reason of the fact that the person is or was a director or officer of our Company or any of our affiliated enterprises.

We do not maintain any policy of directors’ and officers’ liability insurance that insures its directors and officers against the cost of defense, settlement or payment of a judgment under any circumstances.

<div align='center'>II-1</div>

ITEM 15. RECENT SALES OF UNREGISTERED SECURITIES

The following information represents securities sold by the Company within the past three years which were not registered under the Securities Act.

On May 3, 2022, the Company issued an aggregate of 16,000,000 shares of Common Stock to seven (7) holders upon their conversion of 2,000,000 Series B Convertible Preferred Stock.

On November 17, 2022, the Company issued an aggregate of 1,000,000 shares of Common Stock to the two (2) accredited investors in the private placement offering

On August 21, 2023, the Company issued 320,000 shares of Common Stock to an accredited investor in the private placement offering

On November 14, 2023, the Company issued 3,000,000 shares of Common stock and warrants to purchase 1,500,000 shares of common stock, exercisable for a period of 3 years, at the exercise price of $0.80 per shares to investors that previously consideration of the $1,150,000 of funds previously received from these investors, in accordance with instructions and consents from these investors

On November 14, 2023, the